India’s pharmaceutical industry is entering a phase of heightened operational caution as the ongoing Iran conflict starts affecting shipping routes, freight costs and procurement cycles across West Asia. Companies are now prioritising supply continuity and inventory security over short-term cost efficiency, reflecting broader concerns about global trade disruptions and energy-linked inflationary pressures.

According to a report, drug manufacturers are increasing buffer inventories and renegotiating contracts with suppliers and logistics providers to reduce the risk of supply interruptions. Industry executives indicated that while current disruptions remain manageable, a prolonged conflict could materially impact operating profitability through higher transportation, fuel and raw material expenses.

The Indian pharmaceutical sector has historically maintained strong export resilience during geopolitical crises because medicines are considered essential products. However, the present conflict comes at a time when global supply chains are already dealing with shipping bottlenecks, elevated insurance premiums and fragile trade routes through strategic maritime corridors.

India depends heavily on imported active pharmaceutical ingredients (APIs), specialty chemicals and intermediates for a wide range of generic formulations. Even when direct sourcing from the conflict region is limited, the broader ripple effects on oil prices, container movement and freight availability can quickly feed into manufacturing costs. Executives cited in the report estimate that an extended disruption could reduce operating margins by nearly 50 to 150 basis points across parts of the sector.

The pressure point is not only raw material procurement but also outbound exports. Indian pharmaceutical companies supply medicines to multiple regulated and semi-regulated markets across the Middle East, Africa, Europe and the United States. Any disruption in maritime routes around West Asia could lengthen delivery schedules and increase working capital requirements for exporters.

Several companies are therefore reassessing inventory cycles and shipment planning. Some firms are reportedly building additional stock reserves to ensure uninterrupted deliveries, while others are revisiting contractual clauses with distributors and freight partners to manage sudden cost escalations. The move reflects lessons learned from the Covid-era supply chain shock, when pharmaceutical firms faced acute shortages of ingredients and shipping containers.